Smith & Nephew Dividends - SN.

Stock Name	Stock Symbol	Market	Stock Type
Smith & Nephew Plc	SN.	London	Ordinary Share

	Price Change	Price Change %	Stock Price	Last Trade
	-10.00	-0.89%	1,108.50	13:25:10

Open Price	Low Price	High Price	Close Price	Previous Close
1,117.00	1,103.00	1,118.00		1,118.50

more quote information »

Industry Sector
HEALTH CARE EQUIPMENT & SERVICES

Smith & Nephew SN. Dividends History

Announcement Date	Type	Currency	Dividend Amount	Period Start	Period End	Ex Date	Record Date	Payment Date	Total Dividend Amount
28/07/2022	Interim	USX	14.4	31/12/2021	31/12/2022	29/09/2022	30/09/2022	26/10/2022	0
22/02/2022	Final	USX	23.1	31/12/2020	31/12/2021	31/03/2022	01/04/2022	11/05/2022	37.5
29/07/2021	Interim	USX	14.4	31/12/2020	31/12/2021	30/09/2021	01/10/2021	27/10/2021	0
18/02/2021	Final	USX	23.1	31/12/2019	31/12/2020	01/04/2021	06/04/2021	12/05/2021	37.5
29/07/2020	Interim	USX	14.4	31/12/2019	31/12/2020	01/10/2020	02/10/2020	28/10/2020	0
20/02/2020	Final	USX	23.1	31/12/2018	31/12/2019	02/04/2020	03/04/2020	06/05/2020	37.5
31/07/2019	Interim	USX	14.4	31/12/2018	31/12/2019	03/10/2019	04/10/2019	30/10/2019	0
07/02/2019	Final	USX	22	31/12/2017	31/12/2018	04/04/2019	05/04/2019	08/05/2019	36
26/07/2018	Interim	USX	14	31/12/2017	31/12/2018	04/10/2018	05/10/2018	31/10/2018	0
08/02/2018	Final	USX	22.7	31/12/2016	31/12/2017	05/04/2018	06/04/2018	09/05/2018	35
27/07/2017	Interim	USX	12.3	31/12/2016	31/12/2017	05/10/2017	06/10/2017	01/11/2017	0
09/02/2017	Final	USX	18.5	31/12/2015	31/12/2016	30/03/2017	31/03/2017	10/05/2017	30.8
28/07/2016	Interim	USX	12.3	31/12/2015	31/12/2016	06/10/2016	07/10/2016	25/10/2016	0
04/02/2016	Final	USX	19	31/12/2014	31/12/2015	21/04/2016	22/04/2016	11/05/2016	30.8
30/07/2015	Interim	USX	11.8	31/12/2014	31/12/2015	08/10/2015	09/10/2015	27/10/2015	0
05/02/2015	Final	USX	18.6	31/12/2013	31/12/2014	16/04/2015	17/04/2015	06/05/2015	29.6
01/08/2014	Interim	USX	11	31/12/2013	31/12/2014	22/10/2014	24/10/2014	11/11/2014	0
06/02/2014	Final	USX	17	31/12/2012	31/12/2013	20/04/2014	22/04/2014	07/05/2014	27.4
01/08/2013	Interim	USX	10.4	31/12/2012	31/12/2013	09/10/2013	11/10/2013	29/10/2013	0
07/02/2013	Final	USX	16.2	31/12/2011	31/12/2012	17/04/2013	19/04/2013	08/05/2013	26.1
02/08/2012	Interim	USX	9.9	31/12/2011	31/12/2012	10/10/2012	12/10/2012	30/10/2012	0
02/02/2012	Final	USX	10.8	31/12/2010	31/12/2011	18/04/2012	20/04/2012	09/05/2012	17.4
05/08/2011	Interim	USX	6.6	31/12/2010	31/12/2011	12/10/2011	14/10/2011	01/11/2011	0
10/02/2011	Final	USX	9.82	31/12/2009	31/12/2010	01/05/2011	03/05/2011	19/05/2011	15.82
05/08/2010	Interim	USX	6	31/12/2009	31/12/2010	13/10/2010	15/10/2010	02/11/2010	0
12/02/2010	Final	USX	8.93	31/12/2008	31/12/2009	21/04/2010	23/04/2010	12/05/2010	14.39
30/07/2009	Interim	USX	5.46	30/12/2008	30/06/2009	14/10/2009	16/10/2009	03/11/2009	0
12/02/2009	Final	USX	8.12	31/12/2007	31/12/2008	15/04/2009	17/04/2009	08/05/2009	13.58
07/08/2008	Interim	USX	4.96	28/12/2007	28/06/2008	15/10/2008	17/10/2008	07/11/2008	0
07/02/2008	Final	USX	7.38	31/12/2006	31/12/2007	16/04/2008	18/04/2008	09/05/2008	11.89
02/08/2007	Interim	USX	4.51	30/12/2006	30/06/2007	17/10/2007	19/10/2007	09/11/2007	0
08/02/2007	Interim	USX	3.41	31/12/2005	31/12/2006	18/04/2007	20/04/2007	11/05/2007	0
08/02/2007	Final	USX	0	31/12/2005	31/12/2006	01/01/1970	01/01/1970	01/01/1970	5.62
27/07/2006	Interim	USX	2.21	01/01/2006	01/07/2006	18/10/2006	20/10/2006	10/11/2006	0
09/02/2006	Final	USX	3.5	31/12/2004	31/12/2005	19/04/2006	21/04/2006	12/05/2006	5.6
04/08/2005	Interim	USX	2.1	30/12/2004	30/06/2005	19/10/2005	21/10/2005	11/11/2005	0
03/02/2005	Final	USX	3.2	31/12/2003	31/12/2004	20/04/2005	22/04/2005	13/05/2005	5.1
05/08/2004	Interim	USX	1.9	03/01/2004	03/07/2004	20/10/2004	22/10/2004	12/11/2004	0
05/02/2004	Final	USX	3.1	31/12/2002	31/12/2003	21/04/2004	23/04/2004	14/05/2004	4.95
31/07/2003	Interim	USX	1.85	28/12/2002	28/06/2003	13/08/2003	15/08/2003	12/09/2003	0
07/02/2003	Final	USX	3	31/12/2001	31/12/2002	20/04/2003	22/04/2003	16/05/2003	4.8
01/08/2002	Interim	USX	1.8	30/12/2001	30/06/2002	16/10/2002	18/10/2002	15/11/2002	0
07/02/2002	Final	USX	2.9	31/12/2000	31/12/2001	17/04/2002	19/04/2002	17/05/2002	4.65
02/08/2001	Interim	USX	1.75	30/12/2000	30/06/2001	07/11/2001	09/11/2001	05/12/2001	0
15/02/2001	Final	USX	2.8	31/12/1999	31/12/2000	18/04/2001	20/04/2001	18/05/2001	4.5
05/07/2000	Special	USX	37.14	31/12/1999	31/12/2000	07/08/2000	04/08/2000	11/08/2000	0
08/08/2000	Interim	USX	1.7	01/01/2000	01/07/2000	06/11/2000	10/11/2000	06/12/2000	0
23/02/2000	Final	USX	4	31/12/1998	31/12/1999	02/05/2000	08/05/2000	02/06/2000	6.5
09/08/1999	Interim	USX	2.5	03/01/1999	03/07/1999	01/11/1999	05/11/1999	08/12/1999	0
25/02/1999	Final	USX	3.8	31/12/1997	31/12/1998	04/05/1999	10/05/1999	04/06/1999	6.2
26/02/1998	Final	USX	3.8	31/12/1996	31/12/1997	01/06/1998	05/06/1998	01/07/1998	6.2

Top Dividend Posts

Top Posts
Posted at 07/12/2022 15:38 by suetballs https://www.telegraph.co.uk/news/2022/12/05/faulty-knee-replacements-given-10000-patients/ Glad this wasn't sn. Suet Read Full Thread Follow Reply
Posted at 04/11/2022 17:32 by cerrito As a SN. holder I listened to most of the recording of yesterday's webcast. Alot of good stuff especially in logistics and optimization of inventory and US improvement but what stopped me pushing the buy button was not so much the supply shortages(especially semi conductors and resins) but rather that in the Q&A the difficulty they were having on passing on cost increases came up 2/3 times. Read Full Thread Follow Reply
Posted at 03/11/2022 10:19 by disc0dave45 Seem to be following the same stocks!From the healthcare sector I've got SN on my watchlist and good to see they are in line. Some of the constraining factors (materials and staff shortages, FX headwinds) could develop into major issues but who knows. Read Full Thread Follow Reply
Posted at 28/7/2022 12:47 by essentialinvestor Surprised that no one commented on the large CEO share dump a few week back - Those shares granted in lieu of the lapsed options in his previous role on taking the SN position. Read Full Thread Follow Reply
Posted at 28/7/2022 12:44 by essentialinvestor £13/4 bn to take this out - plus their £2 bn approx in net debt. Is SN. worth £15 bn...looks a stretch to me but never say never. Stryker already carry a lump of debt, realistically only leaves JnJ imv. Read Full Thread Follow Reply
Posted at 28/7/2022 08:47 by essentialinvestor Can't see previous FY earnings estimates being achieved as SN now appear to be guiding lower on margin for the full year ?. Read Full Thread Follow Reply
Posted at 28/7/2022 07:22 by roguetraderuk i have mentioned this margin issue on china before. i was surprised no analysts looked at it over the past few months. hence the "surprise" today. since china implemented zero covid its essentially put sn supply china issues in that zone into a semi permanent state. its quite poss they continue with this for a few years, so you are going to have tough comps on this issue til the end of the year now. so you are having to set back equilibrium towards the end of the year. areas of past support are around 1050 and there is a lt gap at 965. the former is quite poss and i wouldnt rule out the latter if the general mkt softens. Read Full Thread Follow Reply
Posted at 15/6/2022 14:47 by pdosullivan I doubled my holding in this one earlier today. It makes no sense for SN/ to be trading 2% above the COVID trough when electives were cancelled etc. Read Full Thread Follow Reply
Posted at 24/4/2022 09:59 by chamer1 With a trading update imminent on Thursday and much to be positive about with this company I think you will be lucky to see the low 12s again, unless the general market is very poor for the first part of the week and SN. tracks it down unavoidably. I think now is time to stay invested and we could see £18 by the end of 2022 Read Full Thread Follow Reply
Posted at 17/12/2021 14:13 by roguetraderuk some advice re sn. the share price will begin to outperform when the mkt believes elected surgery for sn. has turned the corner. it will likely go mkt perform as others start giving signals (stryker, medtronic, intuitive etc) but as i say the big outperformance will come when the company points to a return to trend growth. demand issue and supply chains issues all due to covid and the variants are extending the point of turn in trend. i think it should reach equilibrium by q2 2022, i suspect the shares will bottom by then if not sooner. it all depends on the news and if its leaked and other news from others in the area. i dont think they will get too much cheaper as i would expect the americans to start sniffing. there is plenty to put right at sn. but that means a large upside for any buyer. personally i think they will stay independant until jnj do their split and the jnj arm likely picks up sn. but we will see. if they get cheap enough (10 quid or lower) someone may step up earlier. given that they are likely to underperfrom their peers next year, i wouldnt expect outperformance from here now, but of course i cant see the future and a bid would change all that. Read Full Thread Follow Reply

Your Recent History

LSE

SN.

Smith & Ne..

Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Advertise Here

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil

ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico

ADVFN France ADVFN US

P: V: D:20230131 13:40:37